The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Abilify Maintena

400 milligram(s) Powder and solvent for suspension for injection

Otsuka Pharmaceutical Netherlands B.V.EU/1/13/882/002,004

Main Information

Trade NameAbilify Maintena
Active SubstancesAripiprazole
Strength400 milligram(s)
Dosage FormPowder and solvent for suspension for injection
Licence HolderOtsuka Pharmaceutical Netherlands B.V.
Licence NumberEU/1/13/882/002,004

Group Information

ATC CodeN05AX Other antipsychotics
N05AX12 aripiprazole


Licence Issued30/01/2014
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed


Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back